Mirena IUD Lawsuit 2026: Who Qualifies, Which Injuries Count & How to File
The large Mirena multidistrict litigations are closed — the final MDL ended December 8, 2020 — and as of 2026 most firms have stopped taking new Mirena cases. Individual lawsuits remain possible, and new breast-cancer claims against Bayer are in early stages. This guide covers who still qualifies, which injuries count, and how filing works.
Key facts
- Mirena is Bayer's hormonal (levonorgestrel) IUD — a different device from the copper Paragard, and its litigation took a different path.
- Two federal MDLs ran in New York: MDL 2434 (perforation and migration) and MDL 2767 (pseudotumor cerebri/IIH); the last one closed on December 8, 2020.
- Bayer's documented 2018 settlement totaled $12.2 million across roughly 4,800 perforation and migration cases.
- The pseudotumor cerebri claims were dismissed entirely — in 2016, affirmed on appeal in 2017, and again in 2019 — with no settlements ever paid.
- A new chapter opened in 2024: breast-cancer claims against Bayer are in early stages, with no settlements reached.
For video explainers of similar mass-tort cases: Problem Solved on YouTube.
Mirena vs. Paragard: two different devices, two different lawsuits
An IUD is a small, T-shaped device a clinician places inside the uterus to prevent pregnancy — and the similarities between Mirena and Paragard end there. Mirena is Bayer's hormonal IUD: it releases levonorgestrel, a synthetic progestin hormone. Paragard contains copper and no hormones at all.
The lawsuits reflect it. Mirena claims centered on uterine perforation, device migration, and — in a separate track — pseudotumor cerebri, alleged to be linked to the hormone. The Paragard litigation, covered in our Paragard lawsuits guide, is about the copper device fracturing during removal. Your medical records name the device — and that name decides which litigation, if any, fits your story.
The injuries the Mirena claims center on
Claims against Bayer fell into two physical-injury groups, plus a newer one now emerging. The first is mechanical — the device perforates the uterine wall, embeds in the lining, migrates, or is expelled — with warning signs like sharp pelvic pain, unexplained bleeding, inability to feel the IUD string, and digestive complaints if it has traveled outside the uterus.
The second group is neurological: pseudotumor cerebri — also called idiopathic intracranial hypertension, or IIH — is pressure buildup inside the skull that mimics a brain tumor. It can cause severe headaches, balance problems, blurred vision, and permanent vision loss in the worst cases. Plaintiffs alleged Mirena's hormone caused it; courts demanded stronger proof. The newest group, raised in 2024, alleges a link between Mirena's hormone and breast cancer — still in early stages.
What actually happened in court
Multidistrict litigation, or MDL, is a procedure moving many similar federal lawsuits before a single judge for coordinated pretrial handling. Two Mirena MDLs ran in the Southern District of New York: MDL 2434 (perforation and migration) and MDL 2767 (pseudotumor cerebri).
The perforation track produced the money: Bayer's documented 2018 settlement totaled $12.2 million across roughly 4,800 perforation and migration cases, with reported payouts modest and varying by severity. The pseudotumor track produced nothing — dismissed in 2016 after the plaintiffs' experts were excluded under the Daubert standard for unreliable scientific methods; affirmed by the Second Circuit in 2017, with a second round dismissed in 2019. No settlements were ever paid for IIH claims.
The final Mirena MDL closed on December 8, 2020; as of 2026, most firms have stopped accepting new Mirena cases — a direct consequence of how the evidence battles were lost.
The 2024 breast-cancer chapter
Not every door closed. In 2022, a California plaintiff filed a class action alleging that Bayer withheld information about a possible link between Mirena and breast cancer; a federal judge allowed the case to proceed over Bayer's dismissal effort. More claims followed through 2024, and — unlike the closed MDLs — this track remains in early stages with no settlements reached, much as second waves revived the Zofran birth-defect litigation. Ask specifically about the breast-cancer track: it is the only one with open momentum.
Who still qualifies in 2026
Closed MDLs do not outlaw new lawsuits — they only mean there is no longer a coordinated federal proceeding to join. Individual suits against Bayer remain legally possible. The honest difficulty is finding counsel: most mass-tort firms stopped taking Mirena cases after the 2020 closure, and IIH claims face the steep precedent of the dismissals. Realistic pathways: a perforation or migration injury still has the strongest historical basis; a breast-cancer diagnosis belongs to the newest track; an IIH diagnosis faces the hardest evidentiary road.
Timing matters enormously: every state sets its own statute of limitations, often one to three years, and many apply a discovery rule starting the clock when you reasonably should have known the device caused your injury. Had Mirena removed without injury? You almost certainly have no claim — compensation is for injuries, not the scare. Keep your implantation and removal records, imaging, and surgical reports.
What filing actually involves
A case begins with a free review of the device you had, a documented injury, and whether your state's deadline has passed. Most firms work on contingency — commonly around 33% to 40% of any recovery — so you pay nothing upfront. Concretely: if a case settles for $300,000 with a 33% fee, the fee is $99,000 and $201,000 goes to the client before costs. Compensation varies widely by case, and because most settlements are confidential, no reliable public per-case figures exist beyond the documented historical totals.
If no firm will take your case, that is information too. Never pay a fee upfront — any attorney who demands one is a red flag.
Who Benefits From This — and Who Does Not
Who benefits:
People with a perforation or migration injury from Mirena. How: Bayer's documented 2018 settlement totaled $12.2 million across roughly 4,800 perforation and migration cases (MDL 2434).
People with a breast-cancer diagnosis after Mirena since 2024. How: the new chapter opened in 2024 is still in its early stages, and an individual suit against Bayer is legally possible even though the MDLs are closed.
People who get their injury and timing assessed. How: nothing bars an individual suit against Bayer if your injury and timing support one.
Who does not benefit:
People with pseudotumor cerebri/IIH claims hoping for a settlement. Why: those claims were dismissed entirely — in 2016, affirmed on appeal in 2017, and again in 2019 — with no settlements ever paid.
People expecting most firms to take new Mirena cases. Why: most firms stopped taking new Mirena cases, so attorneys handling individual cases must be sought out specifically.
People expecting a quick settlement. Why: the MDLs are closed, the last one ending on December 8, 2020, and no settlements have been reached in the breast-cancer chapter.
Related reading: Paragard Lawyer 2026.
Frequently asked questions
Can I still file a Mirena lawsuit in 2026?
Yes, legally. The MDLs are closed, but nothing bars an individual suit against Bayer if your injury and timing support one — though most firms stopped taking new Mirena cases, so look for attorneys handling the breast-cancer track or individual perforation claims.
Has the FDA recalled Mirena?
No. The FDA has never recalled Mirena, and the device remains on the market worldwide. The litigation concerns alleged complications, not a government recall.
What did the Mirena settlement pay?
Bayer's documented 2018 settlement totaled $12.2 million across roughly 4,800 perforation and migration cases, with reported payouts modest and varying by severity. Nothing was ever paid for the IIH claims, and the breast-cancer claims have not settled.
Is the Mirena case a class action?
No. The Mirena cases were filed as individual lawsuits coordinated in federal MDLs, not as a class action. A separate class action about breast cancer was filed in California in 2022 and allowed to proceed, but that is a distinct, newer case.
How is a Mirena lawsuit different from a Paragard lawsuit?
Mirena is Bayer's hormonal (levonorgestrel) IUD, while Paragard is a hormone-free copper IUD. Mirena claims focus on perforation, migration, and IIH; Paragard claims focus on the device fracturing during removal. They are separate litigations with separate defendants and separate injury theories.
Who benefits from a Mirena lawsuit, and who does not?
People with a perforation or migration injury benefit most: Bayer's documented 2018 settlement totaled $12.2 million across roughly 4,800 perforation and migration cases. People with pseudotumor cerebri/IIH claims do not benefit from hoping for a settlement: those claims were dismissed entirely, in 2016, affirmed on appeal in 2017, and again in 2019, with no settlements ever paid. To start, check your injury and timing first, then look specifically for attorneys handling individual Mirena cases, since most firms stopped taking new Mirena cases.
This article is general information, not legal advice. Talk to a licensed attorney in your state about your specific situation.